PlantForm Corporation

Signing ceremony in Brazil to mark PlantForm Corporation and Bio-Manguinhos/Fiocruz's agreement to co-develop a biosimilar pembrolizumab for lung cancer using PlantForm's plant-based vivoXPRESS manufacturing system.

PRESS RELEASE: U.S. Patent Granted for Made-in-Canada Ricin Antibody Technology

The U.S. Patent Office has granted a patent for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of research and development by AntoXa Corporation under contract with Defence Research and Development Canada (DRDC), an Agency of the Canadian Department of National Defence.

AntoXa, a wholly-owned subsidiary of PlantForm Corporation, has an exclusive license from DRDC to develop and produce the PhD9 monoclonal antibody treatment in plants for sale in markets worldwide.

Read the full press release:

U.S. Patent Granted for Made-in-Canada Ricin Antibody Technology GUELPH, Ont., CANADA, Feb. 27, 2023 — The U.S. Patent Office has granted a patent for a plant-based manufacturing process to produce an antibody for treatment of ricin exposure, an outcome of research and development by AntoXa Corporation under contract with Defence Research & Development Canada (...

Good news for Ontario: the provincial government is introducing a new policy that requires less expensive versions of biologic drugs to be offered to patients.

Under the new policy, there will be a nine-month transition period that is set to start March 31.

Ontario’s new drug plan will require a swap of brand-name biologic medications for cheaper versions The mandatory switching policy - already adopted in B.C. and Alberta - will save money and better ensure the long-term sustainability of the province’s drug plan, according to a government official